Advertisement
Australia markets closed
  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     
  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     
  • AUD/USD

    0.6695
    +0.0015 (+0.22%)
     
  • OIL

    80.00
    +0.77 (+0.97%)
     
  • GOLD

    2,419.80
    +34.30 (+1.44%)
     
  • Bitcoin AUD

    99,851.36
    -470.73 (-0.47%)
     
  • CMC Crypto 200

    1,368.02
    -5.83 (-0.42%)
     
  • AUD/EUR

    0.6155
    +0.0016 (+0.26%)
     
  • AUD/NZD

    1.0905
    -0.0001 (-0.01%)
     
  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     
  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

Genetron Health Reports Unaudited Second Quarter 2022 Financial Results

Genetron Holdings Limited
Genetron Holdings Limited

BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022.

Recent Business Highlights

  • Received College of American Pathologists (CAP) Accreditation for its laboratory in Maryland.

  • Presented 27 new research abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and American Association for Cancer Research (AACR) 2022 Annual Meeting, highlighting Genetron Health's patented One-Step™ Seq Method and core products including Onco PanScan™, for use in full-cycle cancer management.

  • Launched the Genetron Health Cancer Early Screening Center, and the Genetron Health Future Science and Technology Experience Hall in Wuxi, Jiangsu Province of East China. The new facilities will further support the development of national projects for early screening for comprehensive prevention & control of liver cancer and the "rural revitalization - medical help" project, as well as to promote the development of science popularization.

  • Launched Onco SonarTM, a 170-gene pan-cancer solid tumor NGS liquid biopsy assay, which includes 106 genes of strong clinical significance and 64 genes that occur in high frequency in main cancer populations. The assay enables informed treatment decisions for advanced solid-tumor cancer patients and identifies treatment options or suitable clinical trials for patients before first-line therapy or amid disease progression.

  • Received CE mark for two new tests, Human B Lymphocyte Minimal Residual Disease Testing Kit Seq-MRD® and FusionScan Plus Kit for Human Multi-Genes.

  • Continued to advance in-hospital efforts with 62 hospital partners, of which 31 were IVD in-hospital partners as of June 30, 2022.

  • Launched COVID-19 testing services in May as part of the local community's routine efforts to manage the pandemic in Beijing.

ADVERTISEMENT

Second Quarter 2022 Financial Highlights

  • Generated total revenue of RMB 137.7 million (US $20.6 million) in the second quarter of 2022, representing a 1.9% decrease over the same period in 2021.

    • LDT revenue was RMB 114.9 million (US $17.1 million), representing a 31.8% increase over the same period in 2021, including RMB 48.9 million (US $7.3 million) of COVID-19 testing service revenue.

    • IVD revenue was RMB 9.3 million (US $1.4 million), representing a 78.8% decrease year-over-year.

    • Development services revenue was RMB 13.6 million (US $2.0 million), representing a 42.8% increase over the same period in 2021.

Second Quarter 2022 Unaudited Financial Results

Total revenue for the second quarter of 2022 decreased by 1.9% to RMB 137.7 million (US $20.6 million) in the second quarter of 2022 from RMB 140.5 million in the same period of 2021.

Diagnosis and monitoring revenue decreased by 5.2% to RMB 124.2 million (US $18.5 million) in the second quarter of 2022 from RMB 131.0 million in the same period of 2021, primarily attributable to a decrease in revenue from the IVD product sales.

  • Revenue generated from the provision of LDT services increased by 31.8% to RMB 114.9 million (US $17.1 million) during the second quarter of 2022 from RMB 87.1 million in the same period of 2021. This increase was primarily driven by the COVID-19 testing service revenue of RMB 48.9 million (US $7.3 million), which was included in our second quarter sales of LDT services and offset by decreases in diagnosis and monitoring and early screening services. LDT diagnostic tests, excluding COVID-19 testing, sold in the second quarter 2022 totaled approximately 5,292 units, representing a decrease of 22.6% compared to the number of LDT diagnostic tests sold in the same period of 2021. The decrease was primarily driven by the COVID-19 pandemic situation in major Chinese cities.

  • Revenue generated from the sale of IVD products decreased by 78.8% to RMB 9.3 million (US $1.4 million) in the second quarter of 2022 from RMB 43.8 million in the second quarter of 2021. The decrease was primarily driven by the COVID-19 pandemic situation in major Chinese cities.

Revenue generated from development services increased by 42.8% to RMB 13.6 million (US $2.0 million) in the second quarter of 2022, from RMB 9.5 million in the same period of 2021. The increase was primarily driven by the increase in biopharma services.

Gross profit decreased by 40.6% to RMB 56.1 million (US $8.4 million) in the second quarter of 2022 from RMB 94.5 million in the same period of 2021. Gross margin decreased to 40.7% for the second quarter of 2022, compared to 67.2% in the same period of 2021, primarily driven by product mix shift and the low gross margins of COVID-19 testing services resulting from government pricing protocols.

Operating expenses increased by 16.2% to RMB 226.2 million (US $33.8 million) for the three months ended June 30, 2022, from RMB 194.6 million in the same period of 2021.

Selling expenses increased by 7.0% to RMB 94.7 million (US $14.1 million) in the second quarter of 2022 from RMB 88.5 million in the same period of 2021. Selling expenses as a percentage of revenues increased to 68.7% in the second quarter of 2022 from 63.0% in the same period of 2021. The growing number of salespeople primarily drove the increase.

Administrative expenses increased by 10.2% to RMB 60.1 million (US $9.0 million) in the second quarter of 2022 from RMB 54.6 million in the same period of 2021. Administrative expenses as a percentage of revenues increased to 43.7% in the second quarter of 2022 from 38.8% in the second quarter of 2021. The increase was mainly driven by increased administrative costs associated with conducting COVID-19 testing.

Research and development expenses increased by 9.8% to RMB 61.6 million (US $9.2 million) in the second quarter of 2022 from RMB 56.2 million in the same period of 2021. Research and development expenses as a percentage of revenues increased to 44.7% in the second quarter of 2022 from 40.0% in the same period of 2021. The increases were driven by higher R&D headcount and related expenses, including product development and clinical trial activities.

As a result of the above, operating loss was RMB 170.1 million (US $25.4 million) for the three months ended June 30, 2022, compared to RMB 100.2 million for the three months ended June 30, 2021.

Finance costs-net increased to RMB 66.1 million (US $9.9 million) in the second quarter of 2022 from finance income-net of RMB 8.0 million in the same period of 2021. The increase was driven by the foreign currency exchange loss due to the significant change in exchange rate between RMB and USD.

Loss for the period was RMB 236.2 million (US $35.3 million) for the three months ended June 30, 2022, compared to RMB 92.1 million for the three months ended June 30, 2021.

Non-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, was RMB 228.0 million (US $34.0 million) for the three months ended June 30, 2022, compared to RMB 79.6 million for the three months ended June 30, 2021. Please refer to the section in this press release titled "Non-IFRS Financial Measures" for details.

Basic loss per ordinary share for loss attributable to owners of the Company was RMB 0.51 (US $0.08) for the second quarter of 2022, compared with a basic loss per ordinary share for loss attributable to owners of the Company of RMB 0.20 for the same period of 2021. Excluding share-based compensation expenses, non-IFRS basic loss per ordinary share for loss attributable to owners of the Company was RMB 0.49 (US $0.07) for the second quarter of 2022, compared with non-IFRS basic loss per ordinary share for loss attributable to owners of the Company of RMB 0.17 for the same period of 2021. Diluted loss per ordinary share for loss attributable to owners of the Company is equivalent to basic loss per ordinary share for loss attributable to owners of the Company. Each ADS represents five ordinary shares, par value US$0.00002 per share. Please refer to the section in this press release titled "Non-IFRS Financial Measures" for details.

Cash and cash equivalents and current financial assets at fair value through profit or loss were RMB 472.7 million (US $70.6 million) as of June 30, 2022.

Recent Development
On August 22, 2022, the Company announced that it received a preliminary non-binding offer dated August 21, 2022, to acquire all the outstanding ordinary shares, including those represented by the American depositary shares of the Company (ADSs), for US $0.27 per Ordinary Share or US $1.36 per ADS in cash. Since receiving the proposal, the Company’s Board of Directors has formed a special committee and retained Kroll, LLC as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel to evaluate this offer and other potential strategic alternatives the Company may pursue.

Exchange Rate Information
All translations made in the financial statements or elsewhere in this press release made from RMB into United States dollars ("US$") are solely for convenience and calculated at the rate of US $1.00 = RMB 6.6981, representing the exchange rate as of June 30, 2022, set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate, or at any other rate, on June 30, 2022.

Non-IFRS Financial Measures
The Company uses non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period, which are non-IFRS financial measures, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company help identify underlying trends in the Company's business that could otherwise be distorted by the effect of certain expenses that the Company includes in its loss for the year/period. The Company believes that non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period provide useful information about its results of operations, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.

Non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period and the reconciliation to its most directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Non-IFRS loss and non-IFRS loss per share for loss attributable to owners of the Company for the year/period represent loss for the year/period excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights (if applicable).

Please see the "Unaudited Non-IFRS Financial Measures" included in this press release for a full reconciliation of non-IFRS loss for the year/period to loss for the year/period and non-IFRS loss per share for loss attributable to owners of the Company for the year/period to loss per share for loss attributable to owners of the Company for the year/period.

About Genetron Holdings Limited
Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may", "will," "expect," "anticipate," "target," “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
US:

Philip Trip Taylor
Principal | Gilmartin Group
ir@genetronhealth.com

Media Relations Contact
Yuxin Shou
Genetron Health
yuxin.shou@genetronhealth.com

Edmond Lococo
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com


GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

 

For the three months ended

 

For the six months ended

 

June 30, 2021

 

June 30, 2022

 

June 30, 2021

 

June 30, 2022

 

RMB’000

 

RMB’000

 

US$’000

 

RMB’000

 

RMB’000

 

US$’000

Revenue

140,485

 

 

137,749

 

 

20,565

 

 

232,546

 

 

248,070

 

 

37,036

 

Cost of revenue

(46,021

)

 

(81,656

)

 

(12,191

)

 

(83,533

)

 

(130,507

)

 

(19,484

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

94,464

 

 

56,093

 

 

8,374

 

 

149,013

 

 

117,563

 

 

17,552

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling expenses

(88,516

)

 

(94,695

)

 

(14,137

)

 

(148,187

)

 

(185,539

)

 

(27,700

)

Administrative expenses

(54,577

)

 

(60,136

)

 

(8,978

)

 

(99,180

)

 

(110,378

)

 

(16,479

)

Research and
development expenses

(56,162

)

 

(61,641

)

 

(9,203

)

 

(106,136

)

 

(141,200

)

 

(21,081

)

Net impairment losses on
financial and contract assets

(3,474

)

 

(8,749

)

 

(1,306

)

 

(13,304

)

 

(21,848

)

 

(3,262

)

Other income and gains/(losses) - net

8,081

 

 

(989

)

 

(148

)

 

8,611

 

 

(8,603

)

 

(1,284

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

(194,648

)

 

(226,210

)

 

(33,772

)

 

(358,196

)

 

(467,568

)

 

(69,806

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

(100,184

)

 

(170,117

)

 

(25,398

)

 

(209,183

)

 

(350,005

)

 

(52,254

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finance income

9,447

 

 

541

 

 

81

 

 

5,179

 

 

1,412

 

 

211

 

Finance costs

(1,409

)

 

(66,602

)

 

(9,943

)

 

(3,180

)

 

(62,479

)

 

(9,328

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finance income/(costs) - net

8,038

 

 

(66,061

)

 

(9,862

)

 

1,999

 

 

(61,067

)

 

(9,117

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before
income tax

(92,146

)

 

(236,178

)

 

(35,260

)

 

(207,184

)

 

(411,072

)

 

(61,371

)

Income tax expense

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the period

(92,146

)

 

(236,178

)

 

(35,260

)

 

(207,184

)

 

(411,072

)

 

(61,371

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the Company

(91,820

)

 

(235,215

)

 

(35,116

)

 

(204,574

)

 

(409,587

)

 

(61,149

)

Non-controlling interests

(326

)

 

(963

)

 

(144

)

 

(2,610

)

 

(1,485

)

 

(222

)

 

(92,146

)

 

(236,178

)

 

(35,260

)

 

(207,184

)

 

(411,072

)

 

(61,371

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share for loss attributable to owners of the Company

RMB

 

 

RMB

 

 

USD

 

 

RMB

 

 

RMB

 

 

USD

 

-Basic and diluted

(0.20

)

 

(0.51

)

 

(0.08

)

 

(0.45

)

 

(0.88

)

 

(0.13

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per ADS for loss attributable to owners of the Company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-Basic and diluted

(1.00

)

 

(2.54

)

 

(0.38

)

 

(2.23

)

 

(4.42

)

 

(0.66

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in loss per share computation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-Basic and diluted

459,903,803

 

 

463,590,375

 

 

463,590,375

 

 

458,999,227

 

 

463,231,584

 

 

463,231,584

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ADS used in loss per ADS computation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-Basic and diluted

91,980,761

 

 

92,718,075

 

 

92,718,075

 

 

91,799,845

 

 

92,646,316

 

 

92,646,316

 


GENETRON HOLDINGS LIMITED

UNAUDITED NON-IFRS FINANCIAL MEASURE

 

For the three months ended

 

For the six months ended

 

June 30, 2021

 

June 30, 2022

 

June 30, 2021

 

 

June 30, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

RMB’000

 

RMB’000

 

US$’000

 

RMB’000

 

RMB’000

 

US$’000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the period

(92,146

)

 

(236,178

)

 

(35,260

)

 

(207,184

)

 

(411,072

)

 

(61,371

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based
compensation

12,504

 

 

8,144

 

 

1,216

 

 

21,754

 

 

19,488

 

 

2,909

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-IFRS Loss

(79,642

)

 

(228,034

)

 

(34,044

)

 

(185,430

)

 

(391,584

)

 

(58,462

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the Company

(79,316

)

 

(227,071

)

 

(33,900

)

 

(182,820

)

 

(390,099

)

 

(58,240

)

Non-controlling interests

(326

)

 

(963

)

 

(144

)

 

(2,610

)

 

(1,485

)

 

(222

)

 

(79,642

)

 

(228,034

)

 

(34,044

)

 

(185,430

)

 

(391,584

)

 

(58,462

)

Non-IFRS loss per share for loss attributable to owners of the Company

RMB

 

 

RMB

 

 

USD

 

 

RMB

 

 

RMB

 

 

USD

 

-Basic and diluted

(0.17

)

 

(0.49

)

 

(0.07

)

 

(0.40

)

 

(0.84

)

 

(0.13

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-IFRS loss per
ADS(5 ordinary shares equal to 1 ADS)
for loss attributable to owners of the Company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-Basic and diluted

(0.86

)

 

(2.45

)

 

(0.37

)

 

(1.99

)

 

(4.21

)

 

(0.63

)

 

 

 

 

 

 

Shares used in non-IFRS loss per share computation:

 

 

 

 

 

-Basic and diluted

459,903,803

 

 

463,590,375

 

 

463,590,375

 

 

458,999,227

 

 

463,231,584

 

 

463,231,584

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ADS used in non-IFRS loss per ADS computation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-Basic and diluted

91,980,761

 

 

92,718,075

 

 

92,718,075

 

 

91,799,845

 

 

92,646,316

 

 

92,646,316

 



GENETRON HOLDINGS LIMITED
UNAUDITED REVENUE AND SEGMENT INFORMATION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diagnosis and
monitoring

 

Diagnosis and
monitoring

 

Development
services

 

Total

 

 - provision of
LDT services

 

 - sale of IVD
products

 

 

 

 

 

RMB’000

 

RMB’000

 

RMB’000

 

RMB’000

 

 

 

 

 

 

 

 

Three months ended June 30, 2021

 

 

 

 

 

 

 

Revenue

87,138

 

43,827

 

9,520

 

140,485

Segment profit

61,890

 

31,312

 

1,262

 

94,464

 

 

 

 

 

 

 

 

Three months ended June 30, 2022

 

 

 

 

 

 

 

Revenue

114,872

 

9,283

 

13,594

 

137,749

Segment profit

48,236

 

4,681

 

3,176

 

56,093

 

 

 

 

 

 

 

 

Six months ended June 30, 2021

 

 

 

 

 

 

 

Revenue

158,966

 

59,093

 

14,487

 

232,546

Segment profit

110,701

 

36,534

 

1,778

 

149,013

 

 

 

 

 

 

 

 

Six months ended June 30, 2022

 

 

 

 

 

 

 

Revenue

196,383

 

27,307

 

24,380

 

248,070

Segment profit

100,287

 

13,615

 

3,661

 

117,563



GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

As of December 31, 2021

 

As of June 30, 2022

 

 

RMB’000

 

RMB’000

 

US$’000

ASSETS

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

Property, plant and equipment

 

110,285

 

155,414

 

23,203

Right-of-use assets

 

52,074

 

49,634

 

7,410

Intangible assets

 

20,695

 

27,892

 

4,164

Financial assets at fair value through profit or loss

 

49,780

 

49,201

 

7,346

Prepayments

 

37,610

 

31,460

 

4,697

 

 

 

 

 

 

 

Total non-current assets

 

270,444

 

313,601

 

46,820

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Inventories

 

35,603

 

55,023

 

8,215

Contract assets

 

7,775

 

9,888

 

1,476

Other current assets

 

30,705

 

29,886

 

4,462

Trade receivables

 

282,113

 

309,056

 

46,141

Other receivables and prepayments

 

97,895

 

113,020

 

16,873

Amounts due from related parties

 

597

 

212

 

32

Financial assets at fair value through profit or loss

 

151,443

 

145,128

 

21,667

Derivative financial instruments

 

2,002

 

-

 

-

Cash and cash equivalents

 

639,042

 

327,551

 

48,902

 

 

 

 

 

 

 

Total current assets

 

1,247,175

 

989,764

 

147,768

 

 

 

 

 

 

 

Total assets

 

1,517,619

 

1,303,365

 

194,588


GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS CONTINUED

 

 

As of December 31, 2021

 

As of June 30, 2022

 

 

RMB’000

 

 

RMB’000

 

 

US$’000

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

Borrowings

 

-

 

 

19,194

 

 

2,866

 

Lease liabilities

 

33,865

 

 

29,967

 

 

4,474

 

Other non-current liabilities

 

8,612

 

 

9,181

 

 

1,371

 

Total non-current liabilities

 

42,477

 

 

58,342

 

 

8,711

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

Trade payables

 

55,767

 

 

53,687

 

 

8,015

 

Contract liabilities

 

11,962

 

 

25,996

 

 

3,881

 

Other payables and accruals

 

157,232

 

 

157,172

 

 

23,465

 

Amounts due to related parties

 

3

 

 

1,307

 

 

195

 

Borrowings

 

19,554

 

 

89,958

 

 

13,430

 

Lease liabilities

 

20,572

 

 

21,978

 

 

3,281

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

265,090

 

 

350,098

 

 

52,267

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

307,567

 

 

408,440

 

 

60,978

 

 

 

 

 

 

 

 

 

 

 

Net assets

 

1,210,052

 

 

894,925

 

 

133,610

 

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

Equity attributable to owners of the Company

 

 

 

 

 

 

 

 

 

Share capital

 

61

 

 

61

 

 

9

 

Share premium

 

6,711,234

 

 

6,717,362

 

 

1,002,876

 

Other reserves

 

(69,091

)

 

20,726

 

 

3,095

 

Accumulated losses

 

(5,436,613

)

 

(5,846,200

)

 

(872,814

)

 

 

1,205,591

 

 

891,949

 

 

133,166

 

Non-controlling interests

 

4,461

 

 

2,976

 

 

444

 

 

 

 

 

 

 

 

 

 

 

Total shareholders’ equity

 

1,210,052

 

 

894,925

 

 

133,610